Manila Times Business
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Therapeutic Goods Administration (TGA) of Austr
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Israel, Lebanon agree to conditional ceasefire
2h ago
Quantinuum Announces Pricing of Upsized Initial Public Offering
2h ago
Origin Energy and Landis+Gyr bring large-scale smart gas technology to Australian homes and businesses
2h ago
Compal and Datasection Advance AI Infrastructure for the Production Era
2h ago